Results 91 to 100 of about 65,232 (224)
Ploidy‐Dependent Response to Anticancer Drugs of Human Embryonic Stem Cells
Cell Proliferation, EarlyView.Using isogenic hESCs, differing only in their ploidy level, we show the effect of ploidy on the resistance to anticancer drugs. We demonstrate that polyploidy, by itself, confers sensitivity to chemotherapies, leading to higher apoptosis and delayed proliferation, while the loss of p53 reverses the phenotype, demonstrating higher resistance.
Guy Haim‐Abadi, Nissim Benvenisty
wiley +1 more source
Exploring role of 5hmC as potential marker of chemoresistance
Molecular & Cellular Oncology, 2020 Chemoresistance remains to be a common and significant hurdle with all chemotherapies. Tumors gain resistance by acquiring additional mutations. Some of the chemoresistance mechanisms are known and can be tackled. However, the majority of chemoresistance
Suhas S. Kharat, Shyam K. Sharan
doaj +1 more source
Proper chromosome alignment depends on BRCA2 phosphorylation by PLK1
, 2020 International audienceThe BRCA2 tumor suppressor protein is involved in the maintenance of genome integrity through its role in homologous recombination. In mitosis, BRCA2 is phosphorylated by Polo-like kinase 1 (PLK1).
Miron, Simona +12 more
core +1 more source
Cytology‐First Diagnostic Workflow for Melanoma of Unknown Primary With Molecular Profiling
Cytopathology, EarlyView.Cytology‑first diagnostic workflow for melanoma of unknown primary. Fine‑needle aspiration of an enlarged lymph node enables rapid cytologic evaluation and immunocytochemical confirmation of melanocytic lineage (SOX10). This early cytologic diagnosis facilitates timely surgical excision and comprehensive genomic profiling, supporting integrated ...
Hong Yu +3 more
wiley +1 more source
Population testing for cancer predisposing BRCA1/BRCA2 mutations [PDF]
, 2014 Background: Technological advances raise the possibility of systematic population-based genetic testing for cancer-predisposing mutations, but it is uncertain whether benefits outweigh disadvantages.
Wardle, J
core
BRCA2 gene mutations and coagulation-associated biomarkers
, 2015 Thromboembolic events are the second cause of death in cancer patients, although the mechanisms underlying this increased thromboembolic risk remain unclear.
Pérez Segura, Pedro +13 more
core +1 more source
A guide to transcriptional cyclin‐dependent kinases in cancer
The FEBS Journal, EarlyView.Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin +2 more
wiley +1 more source
Cancer risks in BRCA2 mutation carriers
, 1999 BACKGROUND: Carriers of germline mutations in the BRCA2 gene are known to be at high risk of breast and ovarian cancers, but the risks of other cancers in mutation carriers are uncertain.
Breast Cancer Linkage Consortium, .
core +1 more source
Histopathology, EarlyView.This paper shows that deeper sections reveal additional STICs and HGSCs in risk‐reducing salpingo‐oophorectomy specimens of patients who did not have a STIC or HGSC diagnosis but did develop peritoneal HGSC 10 years after surgery. This adds to the premise that HGSC originates in the fallopian tube.
Anouk B Bouwmeester +17 more
wiley +1 more source
A delayed chemically induced tumorigenesis in Brca2 mutant mice [PDF]
, 2009 [[abstract]]BRCA2 is a breast cancer susceptibility gene. Germline mutations of BRCA2 account for about 10?30% of familial breast cancer cases. Consistent with its tumor-suppressor activity, BRCA2 plays an important role in DNA repair.
Yan, D.-H.;Wen, Y.;Su, L.-K.;Xia, W.;Wang, S.-C.;Zhang, S.;Gan, L.;Lee, D.-F.;Frey, J. A.;Hortobagyi, G. N.;Mien-Chie Hung
core